Immunome Inc. 4

Immunome Inc. Chief Legal Officer & GC Sandra G. Stoneman was granted 38,250 RSUs and 76,500 stock options (exercise price $22.01) as equity compensation on July 23, 2026.

On July 23, 2026, Immunome Inc. Chief Legal Officer & General Counsel Sandra G. Stoneman received an equity compensation package consisting of 38,250 restricted stock units (RSUs) and 76,500 employee stock options with an exercise price of $22.01 per share, with no shares purchased or sold for cash in the market. The RSUs represent the right to receive an equivalent number of Immunome common shares, vesting 25% annually on each anniversary of the grant date, contingent on continued service. The stock options vest 25% on July 23, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, and are exercisable until July 22, 2036. After these awards, Stoneman beneficially owns 43,805 shares of common stock (including or reflecting the new awards as reported), representing a meaningful increase in her equity-linked compensation exposure but reflecting routine incentive grants rather than open-market insider buying or selling.

Filing Facts

CIK

1472012

Ticker

IMNM

Form

4

Source Type

fda

Accession

0001831144-26-000002

Alert Tier

6